William Blair & Company
OTLK icon

William Blair & Company’s Outlook Therapeutics OTLK Stock Holding History

William Blair & Company’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,150
Closed -$28K – 1861
2022
Q3 		$28K Hold
1,150
– – ﹤0.01% 1665
2022
Q2 		$23K Hold
1,150
– – ﹤0.01% 1709
2022
Q1 		$41K Hold
1,150
– – ﹤0.01% 1733
2021
Q4 		$31K Hold
1,150
– – ﹤0.01% 1817
2021
Q3 		$50K Hold
1,150
– – ﹤0.01% 1683
2021
Q2 		$57K Hold
1,150
– – ﹤0.01% 1676
2021
Q1 		$52K Buy
+1,150
New +$44K ﹤0.01% 1659

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

William Blair & Company's OTLK Position: Q4 2022 in Review

William Blair & Company sold out of Outlook Therapeutics (OTLK) in Q4 2022, closing a stake of 1,150 shares — an estimated $28K sold.

William Blair & Company first reported a position in OTLK in Q1 2021 and held it in 7 quarters. The position peaked at $57K in Q2 2021. 75 funds tracked by Wall St. Rank hold OTLK as of Q4 2022.

  • William Blair & Company reported no remaining Outlook Therapeutics position as of Q4 2022 after selling out during the quarter.
  • William Blair & Company sold 1,150 Outlook Therapeutics shares in Q4 2022, an estimated $28K.
  • William Blair & Company first reported a position in Outlook Therapeutics in Q1 2021 and held it in 7 quarters.
  • William Blair & Company's Outlook Therapeutics position peaked at $57K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2022.

Based on William Blair & Company's 13F filing for Q4 2022, filed 10 Feb 2023.